CYTOMX THERAPEUTICS INC's ticker is CTMX and the CUSIP is 23284F105. A total of 143 filers reported holding CYTOMX THERAPEUTICS INC in Q2 2018. The put-call ratio across all filers is 0.09 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $327,638,000 | -20.2% | 64,369 | -0.7% | 0.00% | – |
| Q2 2021 | $410,495,000 | +79.4% | 64,849 | +119.1% | 0.00% | – |
| Q1 2021 | $228,769,000 | -29.3% | 29,595 | -40.1% | 0.00% | – |
| Q4 2020 | $323,381,000 | -1.5% | 49,371 | 0.0% | 0.00% | – |
| Q3 2020 | $328,318,000 | +27.4% | 49,371 | +59.6% | 0.00% | – |
| Q2 2020 | $257,656,000 | +22.5% | 30,931 | +12.8% | 0.00% | – |
| Q1 2020 | $210,296,000 | -26.8% | 27,418 | -20.7% | 0.00% | – |
| Q4 2019 | $287,385,000 | +5.1% | 34,583 | -6.7% | 0.00% | – |
| Q3 2019 | $273,459,000 | -14.7% | 37,054 | +29.7% | 0.00% | – |
| Q2 2019 | $320,489,000 | +21.2% | 28,564 | +16.2% | 0.00% | – |
| Q1 2019 | $264,343,000 | +34.7% | 24,590 | +89.2% | 0.00% | – |
| Q4 2018 | $196,300,000 | -18.4% | 13,000 | 0.0% | 0.00% | – |
| Q3 2018 | $240,500,000 | -13.1% | 13,000 | +7.4% | 0.00% | – |
| Q2 2018 | $276,606,000 | – | 12,100 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Canaan Partners IX LLC | 4,244,381 | $43,378,000 | 100.00% |
| VHCP Management II, LLC | 577,831 | $5,905,000 | 3.56% |
| REGENTS OF THE UNIVERSITY OF CALIFORNIA | 71,366 | $729,000 | 2.45% |
| Casdin Capital, LLC | 234,179 | $2,392,000 | 2.38% |
| BVF INC/IL | 606,138 | $6,192,000 | 1.32% |
| Opaleye Management Inc. | 160,000 | $1,634,000 | 1.09% |
| Redmile Group, LLC | 733,899 | $7,497,000 | 0.72% |
| VHCP Management, LLC | 64,200 | $656,000 | 0.68% |
| Montecito Bank & Trust | 146,544 | $1,497,000 | 0.63% |
| Cormorant Asset Management, LP | 371,636 | $3,796,000 | 0.54% |